Nektar Therapeutics (NASDAQ:NKTR) SVP Stephen K. Doberstein sold 3,461 shares of the company’s stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $31.37, for a total transaction of $108,571.57. Following the completion of the sale, the senior vice president now directly owns 95,913 shares in the company, valued at $3,008,790.81. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.
Nektar Therapeutics stock traded up $0.68 during mid-day trading on Friday, reaching $32.02. The stock had a trading volume of 1,480,671 shares, compared to its average volume of 1,752,666. The stock has a market cap of $5.91 billion, a price-to-earnings ratio of 8.47 and a beta of 2.96. Nektar Therapeutics has a one year low of $29.22 and a one year high of $92.17. The company has a debt-to-equity ratio of 0.21, a current ratio of 14.94 and a quick ratio of 14.83.
Nektar Therapeutics (NASDAQ:NKTR) last announced its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.68) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.71) by $0.03. The company had revenue of $28.22 million for the quarter, compared to analysts’ expectations of $25.45 million. Nektar Therapeutics had a net margin of 55.65% and a return on equity of 37.63%. During the same quarter in the previous year, the business posted ($0.60) EPS. On average, equities analysts expect that Nektar Therapeutics will post -3.14 EPS for the current fiscal year.
NKTR has been the topic of a number of recent research reports. BidaskClub downgraded shares of Nektar Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Thursday, April 18th. Piper Jaffray Companies set a $100.00 target price on shares of Nektar Therapeutics and gave the stock a “buy” rating in a research report on Friday, March 1st. Mizuho reaffirmed a “buy” rating and issued a $81.00 target price on shares of Nektar Therapeutics in a research report on Wednesday, January 23rd. ValuEngine raised shares of Nektar Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, May 1st. Finally, Leerink Swann initiated coverage on shares of Nektar Therapeutics in a research report on Friday, March 15th. They issued a “market perform” rating on the stock. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and nine have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $69.73.
Institutional investors have recently made changes to their positions in the stock. Meeder Asset Management Inc. boosted its stake in Nektar Therapeutics by 150.2% in the 1st quarter. Meeder Asset Management Inc. now owns 798 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 479 shares in the last quarter. Quantamental Technologies LLC bought a new position in Nektar Therapeutics in the 1st quarter worth about $27,000. CSat Investment Advisory L.P. boosted its stake in Nektar Therapeutics by 279.2% in the 4th quarter. CSat Investment Advisory L.P. now owns 1,073 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 790 shares in the last quarter. Laurel Wealth Advisors LLC bought a new position in Nektar Therapeutics in the 4th quarter worth about $39,000. Finally, Sandy Spring Bank bought a new position in Nektar Therapeutics in the 4th quarter worth about $59,000. Institutional investors own 94.90% of the company’s stock.
WARNING: “Stephen K. Doberstein Sells 3,461 Shares of Nektar Therapeutics (NKTR) Stock” was first posted by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this news story on another website, it was illegally stolen and reposted in violation of US and international copyright laws. The legal version of this news story can be accessed at https://transcriptdaily.com/2019/05/18/stephen-k-doberstein-sells-3461-shares-of-nektar-therapeutics-nktr-stock.html.
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology.
Read More: Trading Ex-Dividend Strategy
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.